Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Prices Offering of Senior Notes

NEW YORK (GenomeWeb News) – Affymetrix late on Tuesday announced the pricing of its $105 million offering of senior convertible notes.

The offering of the 4 percent convertible senior notes due 2019 had been previously announced on Monday. The notes will be convertible into Affy's common stock at an initial conversion rate of 170.0319 shares per $1,000 principal amount of notes, subject to adjustment. The conversion rate is equivalent to an initial conversion price of about $5.88 per share, representing a premium of 25 percent to the last reported sale of Affy's stock on the Nasdaq on June 19, when its shares closed at $4.71.

Affy will use net proceeds from the offering to partly fund its $315 million acquisition of eBioscience.

Citigroup and Morgan Stanley are acting as joint book-running managers on the offering. Bank of America Merrill Lynch and RW Baird are co-managers. Affy is granting the offering's underwriters an option to purchase up to $10 million aggregate principal amount of additional notes to cover any over-allotments.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more